Anti-inflammatory adipokines: chemerin, vaspin, omentin concentrations and SARS-CoV-2 outcomes

Kukla, Michał; Menżyk, Tomasz; Dembiński, Marcin; Winiarski, Marek; Garlicki, Aleksander; Bociąga‐Jasik, Monika; Skonieczna, Magdalena; Hudy, Dorota; Maziarz, Barbara; Kuśnierz-Cabała, Beata; Skladaný, Ľubomír; Grgurević, Ivica; Wójcik-Bugajska, Małgorzata; Grodzicki, Tomasz; Stygar, Dominika; Rogula, Tomasz

doi:10.1038/s41598-021-00928-w

Cited by 27 publications

(22 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our observation of elevated levels of chemerin in COVID-19 patients are in contradiction with a recent publication, where serum chemerin levels were lower in COVID-19 patients at day 1 of hospitalization than in healthy controls (31). However, chemerin values in the healthy controls in this study were superior to those described in the literature.…”

Section: Discussioncontrasting

confidence: 99%

Chemerin plasma levels are increased in COVID-19 patients and are an independent risk factor of mortality

et al. 2022

View full text Add to dashboard Cite

BackgroundChemerin is an extracellular protein with chemotactic activities and its expression is increased in various diseases such as metabolic syndrome and inflammatory conditions. Its role in lung pathology has not yet been extensively studied but both known pro- and anti-inflammatory properties have been observed. The aim of our study was to evaluate the involvement of the chemerin/ChemR23 system in the physiopathology of COVID-19 with a particular focus on its prognostic value.MethodsBlood samples from confirmed COVID-19 patients were collected at day 1, 5 and 14 from admission to Erasme Hospital (Brussels – Belgium). Chemerin concentrations and inflammatory biomarkers were analyzed in the plasma. Blood cells subtypes and their expression of ChemR23 were determined by flow cytometry. The expression of chemerin and ChemR23 was evaluated on lung tissue from autopsied COVID-19 patients by immunohistochemistry (IHC).Results21 healthy controls (HC) and 88 COVID-19 patients, including 40 in intensive care unit (ICU) were included. Plasma chemerin concentration were significantly higher in ICU patients than in HC at all time-points analyzed (p<0.0001). Moreover, they were higher in deceased patients compared to survivors (p<0.05). Logistic univariate regression and multivariate analysis demonstrated that chemerin level at day 14 of admission was an independent risk factor for death. Accordingly, chemerin levels correlated with inflammatory biomarkers such as C-reactive protein and tumor necrosis factor α. Finally, IHC analysis revealed a strong expression of ChemR23 on smooth muscle cells and chemerin on myofibroblasts in advanced acute respiratory distress syndrome (ARDS).DiscussionIncreased plasma chemerin levels are a marker of severity and may predict death of COVID-19 patients. However, multicentric studies are needed, before chemerin can be considered as a biomarker of severity and death used in daily clinical practice. Further studies are also necessary to identify the precise mechanisms of the chemerin/ChemR23 system in ARDS secondary to viral pneumonia.

show abstract

Section: Discussioncontrasting

confidence: 99%

Chemerin plasma levels are increased in COVID-19 patients and are an independent risk factor of mortality

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Furthermore, we did not assess the isoforms of chemerin, and the changes in chemerin isoforms may be relevant in different clinical conditions. Finally, there was a difference between chemerin concentration measured using multiplex immunofluorescence assay in the present study in comparison to the previous studies [ 14 , 17 ], which determined chemerin by conventional enzyme-linked immunosorbent assay (ELISA). On the other hand, the differences between the cytokine measurements performed by multiplex methods and ELISA have been previously reported, but with high concordance correlations between the methods [ 45 ].…”

Section: Discussioncontrasting

confidence: 91%

“…There is a paucity of data regarding the kinetics of biomarkers during acute COVID-19 infection, including adipokines. The results of the existing studies are often inconsistent, with some studies reporting higher levels of chemerin [ 14 ], resistin [ 15 ], adiponectin [ 16 ], while others show lower levels of chemerin [ 17 ], and similar concentrations of adiponectin in COVID-19 patients as compared with non-COVID-19 patients [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Chemerin as a Potential Marker of Resolution of Inflammation in COVID-19 Infection

et al. 2022

View full text Add to dashboard Cite

Chemerin is one of the specialized pro-resolving mediators that participate in the early phase of inflammation and contribute to the initiation of the pro-resolving response. There is a paucity of data regarding the time course of chemerin during acute infections. We aimed to evaluate the sequence of inflammatory responses in the acute COVID-19 phase throughout onset and resolution of inflammation. We evaluated changes in selected biomarkers in COVID-19 survivors on the 7-day and 28-day follow up. Chemerin was lower in patients with baseline moderate/severe disease at day 7 compared with asymptomatic patients and individuals with mild illness (7265 [5526–9448] vs. 8730 [6888–11,058] pg/mL; p = 0.03). Only in patients with moderate/severe disease, but not in those with mild symptoms, were chemerin concentrations decreased one week after infection onset compared with baseline (7265 [5526–9448] vs. 8866 [6383–10,690] pg/mL; p < 0.05) with a subsequent increase on the 28-day follow up (9313 [7353–11,033] pg/mL; p < 0.05). Resolution of inflammation in the group of moderate/severe SARS-CoV2 infection was associated with increasing serum concentrations of chemerin, contrary to pro-inflammatory cytokines and adipokines (pentraxin 3, TNFα, resistin, leptin). A similar pattern of angiopoietin-2 dynamics may suggest signs of enhanced vascularization as a consequence of acute SARS-CoV2 infection.

show abstract

“…Visceral (abdominal) adipose tissue is a very fruitful source of adipokines and cytokines, which influence, for example, inflammatory and metabolic processes. There are some studies that suggest COVID-19 is involved in dysregulation of adipokine production [30]. Our study did not show any differences when comparing patients with a BMI < 25 kg/m 2 to those with a BMI ≥ 25 kg/m 2 .…”

Section: Discussioncontrasting

confidence: 67%

Liver Injury in Patients with COVID-19 without Underlying Liver Disease

Pazgan−Simon

Serafińska

Kukla

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

SARS-CoV-2 shows a high affinity for the ACE-2 receptor, present on the epithelial cells of the upper and lower respiratory tract, within the intestine, kidneys, heart, testes, biliary epithelium, and—where it is particularly challenging—on vascular endothelial cells. Liver involvement is a rare manifestation of COVID-19. Material and Methods: We reviewed 450 patients admitted due to the fact of SARS-CoV-2 infection (COVID-19) including 88 with liver injury. Based on medical history and previous laboratory test results, we excluded cases of underlying liver disease. The analysis involved a clinical course of COVID-19 in patients without underlying liver disease as well as the type and course of liver injury. Results: Signs and symptoms of liver injury were present in 20% of patients, mostly presenting as a mixed-type pattern of injury with less common cases of standalone hepatocellular (parenchymal) or cholestatic injury. The liver injury symptoms resolved at the end of inpatient treatment in 20% of cases. Sixteen patients died with no cases where liver injury would be deemed a cause of death. Conclusions: (1) Liver injury secondary to COVID-19 was mild, and in in 20%, the signs and symptoms of liver injury resolved by the end of hospitalization. (2) It seems that liver injury in patients with COVID-19 was not associated with a higher risk of mortality. (3) The underlying mechanism of liver injury as well as its sequelae are not fully known. Therefore, caution and further monitoring are advised, especially in patients whose liver function tests have not returned to normal values.

show abstract

Anti-inflammatory adipokines: chemerin, vaspin, omentin concentrations and SARS-CoV-2 outcomes

Cited by 27 publications

References 59 publications

Chemerin plasma levels are increased in COVID-19 patients and are an independent risk factor of mortality

Chemerin plasma levels are increased in COVID-19 patients and are an independent risk factor of mortality

Chemerin as a Potential Marker of Resolution of Inflammation in COVID-19 Infection

Liver Injury in Patients with COVID-19 without Underlying Liver Disease

Contact Info

Product

Resources

About